European Medicines Agency has published Q&A document on GCP compliance inspections.It clarifies following issues:
- Investigational medicinal products (IMPs) in bioavailability and bioequivalence trials GCP matters
- Expectations of European Union (EU) competent authorities on the use of electronic trial master files
- Records of study subject data relating to clinical trials
Further information: Q&A: Good clinical practice (GCP)
No comments:
Post a Comment